Alpha1 blockers may not improve Lower urinary tract symptoms in females
The European Urological Association guidelines suggest that, relative to placebo, alpha-1 adrenergic receptor blockers (α1- blockers) reduce urinary symptoms and increase maximal flow rate (Qmax) in men with lower urinary tract symptoms (LUTS). However, according to prize-winning abstract presented at the International Continence Society, 2020 virtual annual meeting, the use of α1-blockers on female LUTS should be based on the subjective cause as it has little effects on urologic symptom scores, quality of life, and overall adverse events compared to placebo.
The overall prevalence of female voiding dysfunction is estimated to be between 3% and 39%. However, considering the present lack of standardized diagnostic criteria and clinical guidelines, female LUTS is likely overlooked and underestimated. Moreover, the pathophysiological mechanism of female LUTS remains unclear. The current use of α1-blockers for female LUTS is based on their remarkable effects in the treatment of male LUTS. Published clinical trials evaluating the use of α1-blockers for female LUTS have remained limited in prevalence and participation and have produced contradictory results. For this purpose, researchers of South Korea, conducted a study to assess the effectiveness of alpha-1 adrenergic receptor blockers (α1-blockers) in the treatment of female lower urinary tract symptoms (LUTS).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.